Werfen
Werfen is a private Barcelona-headquartered IVD company that develops, manufactures, and globally distributes diagnostic analyzers, proprietary reagents, and data-management software across hemostasis, acute care, transfusion, autoimmunity, and transplant diagnostics for hospitals, clinical laboratories, and donor/transplant centers in 30+ countries.
- Company typePrivate
- Founded1966
- HeadquartersBarcelona, Spain
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Werfen does
Werfen S.A. is a privately held, Barcelona-headquartered specialized in vitro diagnostics (IVD) company that develops, manufactures, and distributes diagnostic systems, proprietary reagents, and laboratory data-management software to hospitals, clinical laboratories, intensive care units, operating rooms, emergency departments, immunohematology labs, donor centers, and transplant centers across more than 30 countries directly and over 100 territories through distributors.
The company operates across five core diagnostic areas — Hemostasis/Coagulation (ACL TOP Family, HemosIL reagents, ROTEM sigma viscoelastic testing, VerifyNow platelet testing), Acute Care Diagnostics (GEM Premier blood gas family with iQM3 intelligent quality management, GEM Premier ChemSTAT, Hemochron, Avoximeter), Transfusion (Echo Lumena, NEO Iris, Capture-R Ready-Screen/ID, ImmuLINK from the Immucor acquisition), Autoimmunity (Aptiva with PMAT, BIO-FLASH, NOVA View, QUANTA Flash/Lite and QUANTA-Lyser), and Transplant (LIFECODES, MIA FORA NGS, and Omixon NGS-based HLA typing). Underlying platforms combine cartridge-based and automated instrumentation with proprietary reagent chemistries and connectivity software (HemoHub, GEMweb Plus, QUANTA Link) for hospital network integration.
Werfen monetizes through a razor-and-blade model: capital sales of analyzers drive an installed base of recurring high-margin reagent and consumable revenue (HemosIL, QUANTA Flash/Lite, LIFECODES assays), supplemented by software subscriptions (HemoHub, GEMweb Plus, QUANTA Link, ImmuLINK) and professional service contracts. The company has executed an aggressive M&A program — most notably the ~US$2 billion acquisition of Immucor in March 2023 and the October 2024 acquisition of Omixon — to consolidate specialized niches, and reached €2.1 billion in sales as reported in April 2026.
Werfen firmographics
Firmographics- Name
- Werfen
- Legal name
- Werfen S.A.
- Website
- https://werfen.com
- Company type
- Private
- Founded year
- 1966
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Werfen is a private Barcelona-headquartered IVD company that develops, manufactures, and globally distributes diagnostic analyzers, proprietary reagents, and data-management software across hemostasis, acute care, transfusion, autoimmunity, and transplant diagnostics for hospitals, clinical laboratories, and donor/transplant centers in 30+ countries.
- Ownership category
- akta.pro rank
Werfen industry classification
Industry- Product category
- In Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)
- akta.pro secondary industries
- Hematology & Coagulation Diagnostics (HLAHAAAB), Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH), Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
Keywords
Where Werfen is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices9 records
Markets served
Werfen business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Diagnostic Instruments and Systems: Sale of specialized diagnostic analyzers and systems including GEM Premier blood gas analyzers, ACL TOP hemostasis systems, ROTEM viscoelastic testing devices
- Reagents and Consumables: Recurring revenue from proprietary reagents, test kits, and consumables for diagnostic systems including HemosIL reagents, QUANTA Flash/Lite reagents, LIFECODES assays
- Software and IT Solutions: Data management software including HemoHub, GEMweb Plus, QUANTA Link, ImmuLINK for laboratory connectivity and workflow management
- Technical Support and Service: Customer service, technical support, training, and field service for instrument maintenance and optimization
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Werfen product offering
Product offeringCore offering
Werfen develops, manufactures and distributes specialized in vitro diagnostic (IVD) systems, proprietary reagents, consumables, and data-management software across five diagnostic areas: hemostasis (coagulation), acute care diagnostics (blood gas and point-of-care), transfusion medicine, autoimmunity, and transplant diagnostics. The company sells analyzers, cartridge-based testing platforms, and recurring reagents to hospitals, clinical laboratories, intensive care units, operating rooms, donor centers and transplant centers globally through a combination of direct sales and distributors.
Product overview
Werfen is a specialized diagnostics company offering a comprehensive portfolio of diagnostic systems, reagents, and software across five core areas: Hemostasis (coagulation testing), Acute Care Diagnostics (blood gas and point-of-care testing), Transfusion (blood typing and compatibility), Autoimmunity (antibody testing), and Transplant (HLA testing). The product portfolio includes industry-leading analyzers such as the ACL TOP Family and GEM Premier systems,配套 reagents like HemosIL for coagulation and QUANTA for autoimmunity, and connectivity solutions including HemoHub, GEMweb, and QUANTA Link for integrated data management. Key product lines include the ROTEM viscoelastic testing systems for bleeding management, the GEM Premier 7000 with iQM3 for blood gas and hemolysis detection, the Aptiva multi-analyte autoimmune testing platform, and the MIA FORA NGS transplant diagnostics systems acquired through Immucor and Omixon acquisitions.
Differentiator
Problem solved
Functional benefit
Brands
- GEM Premier: Blood gas and critical care testing systems including GEM Premier 5000, 3500, 7000 with iQM3, and GEM Premier ChemSTAT
- ACL TOP
- HemosIL
- ROTEM
- VerifyNow
- BIO-FLASH
- QUANTA Series
- Immucor
- LIFECODES
- MIA FORA
- iQM
- HemoCell
- Omixon
Products and services
- GEM Premier 7000 with iQM3 Blood gas testing system with intelligent quality management (iQM3) that provides lab-quality detection of hemolysis in whole blood at the point of care for acute care settings.
- GEM Premier 5000 Blood gas analyzer for acute care diagnostics delivering fast, actionable results in point of care settings.
- GEM Premier 3500 Point of care blood gas analyzer for acute care diagnostics in hospital settings.
- GEM Premier ChemSTAT Basic metabolic panel analyzer for point of care testing with rapid results in acute care settings.
- ACL TOP Family 70 Series Next-generation hemostasis testing systems that optimize workflow with quality and efficiency for the entire laboratory network, featuring automation, connectivity, automated performance verification and pre-analytical checks.
- ACL TOP Family 50 Series Hemostasis testing systems for laboratory coagulation analysis with automated performance verification and pre-analytical checks.
- ACL AcuStar Automated coagulation analyzer for hemostasis testing with advanced sensitivity and automation capabilities.
- ACL Elite Pro Small coagulation analyzer for hemostasis testing at point of care and laboratory settings.
- ROTEM sigma Easy-to-use, cartridge-based viscoelastic testing system delivering rapid results at the point of care to guide bleeding management and Patient Blood Management programs.
- ROTEM delta Viscoelastic testing system for assessing hemostasis and guiding bleeding management in clinical settings.
- VerifyNow Point of care platelet function testing device used to assess platelet reactivity and guide antiplatelet therapy.
- GEM Hemochron 100 Activated clotting time (ACT) analyzer for point of care hemostasis testing in acute care settings.
- Hemochron Signature Elite Point of care ACT machine for hemostasis testing in acute care and operating room settings.
- Avoximeter 1000E Rapid whole-blood CO-Oximetry testing device for acute care settings.
- Echo Lumena Automated instrument for transfusion diagnostics providing efficient and accurate blood typing and screening for immunohematology laboratories.
- NEO Iris Automated instrument for immunohematology testing and donor-recipient compatibility assessment in transfusion medicine and donor centers.
- Aptiva Multi-analyte testing system using Particle-based Multi-Analyte Technology (PMAT) for autoimmune disease diagnostics.
- BIO-FLASH Chemiluminescent analyzer for autoimmune antibody testing with high sensitivity and specificity.
- NOVA View Automated IFA microscope for reading and interpretation of immunofluorescence assays in autoimmune diagnostics.
- QUANTA-Lyser 3000 Automated instrument for processing ELISA and immunofluorescence assays in autoimmune testing laboratories.
- MIA FORA NGS MFlex Next-generation sequencing HLA typing kits for high-resolution donor-recipient matching in transplant diagnostics.
- HemosIL Reagents Comprehensive line of proprietary coagulation reagents covering general screening, anticoagulant testing, D-Dimer, antiphospholipid syndrome, heparin-induced thrombocytopenia, von Willebrand disease, fibrinolysis, thrombophilia and coagulation factors.
- ILab Taurus Random-access clinical chemistry analyzer for clinical chemistry and pharma-toxicology laboratory testing.
- ILab 650 Automated clinical chemistry analyzer for routine and specialized chemistry testing.
- iQ 200 Automated urine microscopy analyzer for particle analysis in urinalysis testing.
- iChem Velocity Automated urine chemistry analyzer for comprehensive urinalysis testing.
- Triage MeterPro Point of care diagnostic device for cardiometabolic testing, including cardiac markers and diabetes markers.
- GeneXpert Cartridge-based real-time PCR system for molecular diagnostics, including infectious disease testing, critical infections and women's health.
- Capture-R Ready-Screen Automated solid-phase antibody screening assay for detecting unexpected antibodies in donor and patient samples.
- LIFECODES LSA Single antigen assays for detecting and characterizing HLA antibodies in transplant compatibility testing.
Quantifiable outcome
- Over 1 million samples analyzed daily with Werfen systems worldwide
- +2 more outcomes
Companies that use Werfen
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles2 records
Werfen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Werfen partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- DTI FoundationminorPartnership for transplant education in Latin America. Combines Werfen's transplant diagnostics with DTI Foundation's transplant education expertise to advance transplant medicine knowledge in the region.
- LabchecapminorStrategic distribution partnership expanding Werfen's hemostasis portfolio in Northeast Brazil. Labchecap serves as regional distributor for Werfen products.
- Oxford NanoporecoreStrategic collaboration to support development of advanced transplant assays. Combines Werfen's transplant diagnostics expertise with Oxford Nanopore's sequencing technology for next-generation HLA typing and transplant diagnostics.
- HologicminorCo-Marketing and Services Agreement. Strategic partnership for diagnostic market expansion combining Werfen's specialized diagnostics portfolio with Hologic's offerings.
- ImmucorcoreAcquired company specializing in transfusion and transplant diagnostics. Immucor provides comprehensive immunohematology solutions including automated instruments, reagents, and data management software for blood transfusion compatibility testing.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Werfen competitors and assessment
Company assessmentBroad incumbents
- Roche Diagnostics: Roche Diagnostics is the world's largest IVD company with broad menus across chemistry, immunoassay, hematology and point-of-care. It directly overlaps with Werfen in acute care blood gas and hemostasis and is identified as a co-dominant player in point-of-care blood diagnostics.
- Abbott Diagnostics: Abbott Diagnostics is a global IVD incumbent with i-STAT and other point-of-care platforms overlapping Werfen's GEM Premier franchise. It is listed alongside Werfen as a dominant player in point-of-care blood diagnostics.
- Siemens Healthineers: Siemens Healthineers offers broad IVD and laboratory automation solutions including hemostasis (formerly Dade Behring). Comparable as a global IVD incumbent competing with Werfen in coagulation analyzers and integrated lab solutions.
- bioMérieux: bioMérieux is a European-headquartered IVD specialist in microbiology and industrial applications with growing clinical diagnostics presence. Comparable as a similarly sized, specialty-focused European IVD company to Werfen.
- Bio-Rad Laboratories: Bio-Rad is a specialty IVD and life science company with presence in blood typing, immunology quality controls and clinical diagnostics. Comparable as a mid-large specialty diagnostics company with overlapping transfusion and laboratory QC offerings.
Direct peers
- Sysmex Corporation: Sysmex is the global leader in hematology and hemostasis diagnostics with the CS and CA series coagulation analyzers. It is one of the closest direct competitors to Werfen in routine and specialized coagulation testing.
- Diagnostica Stago: Stago is a privately held French specialty IVD company focused exclusively on hemostasis and thrombosis diagnostics. It competes head-to-head with Werfen in coagulation analyzers, reagents and the same clinical laboratory customer base.
- QuidelOrtho: QuidelOrtho (formerly Ortho Clinical Diagnostics) is a leading specialty IVD company in transfusion medicine, blood typing and immunohematology. It directly competes with Werfen's Immucor-based transfusion portfolio and also overlaps in clinical chemistry.
Emerging players
- DiaSorin: DiaSorin is an Italian-headquartered specialty IVD company focused on immunodiagnostics and molecular diagnostics. Comparable as a European specialty IVD company with a similar scale and recurring reagent business model to Werfen.
- Grifols: Grifols operates a Diagnostic division focused on transfusion medicine, blood typing and immunohematology. Comparable to Werfen's Immucor business as a competitor in blood bank and donor-center diagnostics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Werfen social profiles
Digital presenceWerfen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Werfen leadership team
Management profileNumber of profiles
Profiles4 records
Werfen subsidiaries and ownership
Company hierarchySubsidiaries7 records
Werfen funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Werfen M&A and investment
M&A and investmentM&A3 records
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Werfen
What does Werfen do?
Werfen develops, manufactures and distributes specialized in vitro diagnostic (IVD) systems, proprietary reagents, consumables, and data-management software across five diagnostic areas: hemostasis (coagulation), acute care diagnostics (blood gas and point-of-care), transfusion medicine, autoimmunity, and transplant diagnostics. The company sells analyzers, cartridge-based testing platforms, and recurring reagents to hospitals, clinical laboratories, intensive care units, operating rooms, donor centers and transplant centers globally through a combination of direct sales and distributors.
Is Werfen a public or private company?
Werfen is a private company. It is classified as family owned and is currently operating.
When was Werfen founded?
Werfen was founded in 1966. It employs 5,001 to 10,000 people.
Where is Werfen based?
Werfen is headquartered in Barcelona, Spain, in the Europe region.
How does Werfen make money?
Four revenue lines are on record. Diagnostic Instruments and Systems are the primary driver. The others are reagents and Consumables, software and IT Solutions and technical Support and Service.
Who are Werfen's main competitors?
Broad incumbents on record are Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers, bioMérieux and Bio-Rad Laboratories. Direct peers are Sysmex Corporation, Diagnostica Stago and QuidelOrtho. Emerging players are DiaSorin and Grifols.
Does Werfen have an API?
No public API is recorded for Werfen.
What industry is Werfen in?
Werfen's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAHAAAB, Hematology & Coagulation Diagnostics. Its NAICS code is 325413 and its SIC code is 2835.